Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019
James D. Allen, Ted M. Ross
Abstract
Standard-of-care influenza virus vaccines are composed of a mixture of antigens from different influenza viral subtypes. For the first time, lead COBRA H1 and H3 HA antigens, formulated as a bivalent vaccine, have been investigated in animals with preexisting immunity to influenza viruses. The cocktail of COBRA HA antigens elicited more broadly reactive anti-HA antibodies than those elicited by a comparator bivalent wild-type HA vaccine against H1 and H3 influenza viruses isolated between 2009 and 2019.
Topics & Concepts
VirologyBiologyHemagglutinin (influenza)Bivalent (engine)AntigenInfluenza vaccineAntibodyVaccinationAntigenic driftInfluenza A virusVaccine efficacyImmunologyVirusChemistryOrganic chemistryMetalInfluenza Virus Research StudiesRespiratory viral infections researchSARS-CoV-2 and COVID-19 Research